The Subcutaneous Drug Development & Delivery Consortium was established in 2018 to fundamentally improve subcutaneous drug development and delivery. Motivated by this shared goal, members have come together to address key issues in the subcutaneous industry and expand subcutaneous technology use to improve patient outcomes.
To realize this purpose, the Subcutaneous Drug Development & Delivery Consortium focuses on bringing together a diverse group of key members of the subcutaneous community (i.e., industry, academia, regulatory, payers, etc.) in a precompetitive manner to collaboratively share their respective expertise and experiences.
While the Subcutaneous Drug Development & Delivery Consortium has accomplished much since its inauguration in 2018, members are eager to capitalize on recent successes by establishing a comprehensive strategic plan to guide targeted activities and efforts into the future that will ensure members’ ultimate vision and mission will be realized.
Consortium members are:
All members have experience in at least one of the following areas:
Governing Board or non-Governing Board members guide the overall strategic direction of the Subcutaneous Drug Development & Delivery Consortium and steer output development. There are 5 sub-teams, guided by a Problem Statement Roadmap. There are 4 levels of sub-team membership and affiliation:
The SC Consortium provides value to the SC community by:
The Subcutaneous Drug Development & Delivery Consortium is established as a 501 C 6 nonprofit, with a Governing Board composed of 1 primary and 1 backup member from each represented industry organization (~17 companies total) to oversee the Subcutaneous Drug Development & Delivery Consortium’s strategy, direction, and governance of 5 sub-teams
Industry board members contribute a yearly membership fee to secure a board vote – this investment contributes to a pool of shared funds to support ongoing sub-team project work, promotional activities, and consortium management
The Governing Board is composed entirely of contributing biopharmaceutical industry members. Sub-teams include external collaborators / subject matter experts (eg, academics, regulators, etc.) working together to develop outputs around issues outlined in key or selected problem statements. Sub-teams have developed Roadmaps outlining or describing planned activities over the next 5 years
Our sub-teams call for expertise through a variety of advertising outlets, and raise awareness of research milestones via conference presentations and academic journals
The Governing Board meets every 2 months to align on strategic, governance and operational topics. The Board routinely meets with sub-teams to ensure project execution. Charles River Associates (CRA) oversees management of the Subcutaneous Drug Development & Delivery Consortium, including a Microsoft Teams Site for members to collaborate and share materials